Figure 5.

IFN-γ production by peripheral blood mononuclear cells. Cells were incubated with 0 U (control), 100 U or 1,000 U of IL-2, and the concentration of IFN-γ produced was measured in (A) patient A, (B) patient B and (C) patient C prior to, during and subsequent to therapy with the tyrosine kinase inhibitor sunitinib. All data are presented as the mean + standard deviation from triplicate experiments. Arrows indicate the time points when the treatment regimen was changed (from sunitinib to everolimus in patient B, and from sunitinib to sorafenib in patient C). (D) Measurements of IFN-γ concentration on day 0, 60 and 91 are included for each of the healthy donor controls (nos. 1–4). IFN-γ, interferon γ; IL-2, interleukin 2; n.d., no data.